Concepedia

Author

Jeffrey A. Engelman

Massachusetts General HospitalORCID

Also Known As

Engelman, J., Goel, Shom, Gu, Ting Lei, J A Engelman, J. A. Engelman, J. Engelman, J.A. Engelman, Jeffrey A Engelman, Jeffrey A. Engelman, Jeffrey Engelman

873

Publications

84.5K

Citations

131

H-Index

106

Concepts

All Affiliations

Massachusetts General HospitalHarvard UniversityDana-Farber Cancer InstituteBrigham and Women's HospitalBeth Israel Deaconess Medical Center
JA

About

Jeffrey A. Engelman is an author at Massachusetts General Hospital specializing in medicine, oncology, and cell biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

60

76

24.1K

2

Health Sciences

10

10

1.4K

3

Engineering

5

5

2.6K

4

Natural Sciences

2

2

220

5

Public Health

1

1

96

Jeffrey A. Engelman

×

189

Publications

68.5K

Citations

122

H-Index

YearCitations

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge,

New England Journal of Medicine

2010

4.5K

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi,

Science

2007

4.4K

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata,

Science Translational Medicine

2011

3.5K

Systematic identification of genomic markers of drug sensitivity in cancer cells

Mathew J. Garnett, Elena J. Edelman, Sonja J. Heidorn,

Nature

2012

2.5K

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

Vasanthi S. Viswanathan, Matthew J. Ryan, Harshil Dhruv,

Nature

2017

1.9K

<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers

Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou,

Journal of Clinical Oncology

2012

1.5K

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Shohei Koyama, Esra A. Akbay, Yvonne Y. Li,

Nature Communications

2016

1.5K

Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, Dong-Wan Kim, Ranee Mehra,

New England Journal of Medicine

2014

1.4K

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Jeffrey A. Engelman, Liang Chen, Xiaohong Tan,

Nature Medicine

2008

1.3K

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

Ryohei Katayama, Alice T. Shaw, Tahsin Khan,

Science Translational Medicine

2012

1.3K

Page 1